In this study, we aimed to investigate the time course of levels of the fibrinopeptide AαVal541 over a month following a single dose of AAT augmentation therapy in severe deficient AATD patients by pharmacokinetic modeling to evaluate the inhibitory effect of AAT on PR3. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.